NASDAQ:CBAY - CymaBay Therapeutics Stock Price, Forecast & News

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

CymaBay Therapeutics Inc (NASDAQ:CBAY) released its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.37) by $0.01. View CymaBay Therapeutics' Earnings History.

CymaBay Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for CymaBay Therapeutics.

13 brokerages have issued 12 month price targets for CymaBay Therapeutics' stock. Their forecasts range from $2.00 to $18.00. On average, they anticipate CymaBay Therapeutics' share price to reach $6.95 in the next twelve months. This suggests a possible upside of 321.5% from the stock's current price. View Analyst Price Targets for CymaBay Therapeutics.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 10 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CymaBay Therapeutics.

Media coverage about CBAY stock has trended very negative on Tuesday, InfoTrie reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. CymaBay Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for CymaBay Therapeutics.

Some companies that are related to CymaBay Therapeutics include Puma Biotechnology (PBYI), Prothena (PRTA), Satsuma Pharmaceuticals (STSA), BioDelivery Sciences International (BDSI), Sinovac Biotech (SVA), BioSpecifics Technologies (BSTC), Beyondspring (BYSI), Innate Pharma (IPHYF), Progenics Pharmaceuticals (PGNX), AnaptysBio (ANAB), OrganiGram (OGI), Organogenesis (ORGO), Mallinckrodt (MNK), Cue Biopharma (CUE) and Mirum Pharmaceuticals (MIRM).

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Exelixis (EXEL), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Alibaba Group (BABA), Abeona Therapeutics (ABEO), AVEO Pharmaceuticals (AVEO), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE).

CymaBay Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Engine Capital Management LP (7.25%), Boxer Capital LLC (2.91%), State Street Corp (2.05%), Citigroup Inc. (1.96%), Geode Capital Management LLC (1.50%) and LMR Partners LLP (1.30%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Daniel Menold, Kurt Von Emster and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics.

CBAY stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, State Street Corp, Bank of America Corp DE, UBS Group AG, Charles Schwab Investment Management Inc., Cubist Systematic Strategies LLC, Credit Suisse AG and National Asset Management Inc.. View Insider Buying and Selling for CymaBay Therapeutics.

CBAY stock was acquired by a variety of institutional investors in the last quarter, including Engine Capital Management LP, LMR Partners LLP, Boxer Capital LLC, Acadian Asset Management LLC, Renaissance Technologies LLC, Citigroup Inc., Alambic Investment Management L.P. and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for CymaBay Therapeutics.

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBAY stock can currently be purchased for approximately $1.65.

CymaBay Therapeutics has a market capitalization of $113.36 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-72,550,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. CymaBay Therapeutics employs 43 workers across the globe.View Additional Information About CymaBay Therapeutics.

The official website for CymaBay Therapeutics is http://www.cymabay.com/.

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]